selected publications
-
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies.
Journal of virology.
2025
Academic Article
GET IT
Times cited: 2 - Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies. 2025 GET IT
-
Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants.
Immunity.
2023
Academic Article
GET IT
Times cited: 19 -
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer.
Immunity.
2023
Academic Article
GET IT
Times cited: 11 -
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
Cell host & microbe.
2022
Academic Article
GET IT
Times cited: 60 -
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults.
iScience.
2022
Academic Article
GET IT
Times cited: 6 -
Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
Viruses.
2021
Academic Article
GET IT
Times cited: 46 -
Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19.
EMBO molecular medicine.
2021
Academic Article
GET IT
Times cited: 120 -
Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.
Nature protocols.
2021
Review
GET IT
Times cited: 42 -
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
Cell host & microbe.
2021
Academic Article
GET IT
Times cited: 120 -
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
2020
GET IT
Times cited: 47 -
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Cell.
2020
Academic Article
GET IT
Times cited: 226 - Antibody Teamwork against Ebola Virus Disease. Immunity. 2020 Comment GET IT
-
Structural Basis for a Convergent Immune Response against Ebola Virus.
Cell host & microbe.
2020
Academic Article
GET IT
Times cited: 27 -
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
Nature medicine.
2019
Academic Article
GET IT
Times cited: 94 -
NLRP3 inflammasome-activating arginine-based liposomes promote antigen presentations in dendritic cells.
International journal of nanomedicine.
2019
Academic Article
GET IT
Times cited: 19 -
N-glycosylation converts non-glycoproteins into mannose receptor ligands and reveals antigen-specific T cell responses in vivo.
Oncotarget.
2017
Academic Article
GET IT
Times cited: 14 -
Sec61 in antigen cross-presentation.
Oncotarget.
2015
Editorial Article
GET IT
Times cited: 7